TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15735462

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite with 17% EDTA for 1 min followed by 5-ml rinse with 5.25% NaOCl
Number of subjects: 73

Group type: COMPARATOR
Intervention: 1.3% NaOCl with MTAD for 5 min
Number of subjects: 73
Study: 12895193

Group type: EXPERIMENTAL
Intervention: Quinidine (3 mg kg(‐1))
Number of subjects: 48
Study: 10026403

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (Neoral)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 14
Study: 8901755

Group type: EXPERIMENTAL
Intervention: CABG plus ICD
Number of subjects: 724

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Patients judged too unstable for randomization
Number of subjects: 724
Study: 2005163

Group type: EXPERIMENTAL
Intervention: Wrist immobilisation in dorsiflexion
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wrist immobilisation in palmar flexion
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wrist immobilisation in neutral position
Number of subjects: 204
Study: 6383760

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg X min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (initial single infusion)
Number of subjects: 25
Study: 31389509

Group type: EXPERIMENTAL
Intervention: Ropivacaine injection (0.375% at doses of 2.5 ml in each belly of the anterior and middle scalene muscles, guided by ultrasonography)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Skin pressure in each belly of the anterior and middle scalene muscles (control group)
Number of subjects: 38
Study: 27757595

Group type: EXPERIMENTAL
Intervention: Soy nutritional intervention (30 g/day soy protein)
Number of subjects: 26
Study: 27438111

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 579

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: miR-124-3p levels
Number of subjects: 579
Study: 25277170

Group type: EXPERIMENTAL
Intervention: Resection of the primary tumour followed by systemic therapy (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic therapy only (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Number of subjects: 0
Study: 23171166

Group type: EXPERIMENTAL
Intervention: Behaviour Change Counselling (BCC) intervention for glaucoma education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard education without BCC)
Number of subjects: 0
Study: 20175609

Group type: EXPERIMENTAL
Intervention: Family focused treatment
Number of subjects: 58
Study: 17370096

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 0
Study: 15734713

Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physical activity treatment designed to increase TEE by 7%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physical activity treatment designed to increase TEE by 11%
Number of subjects: 13
Study: 12392115

Group type: EXPERIMENTAL
Intervention: Leg isometric exercise training for 5 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Arm isometric exercise training for 5 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 27
Study: 10433672

Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer with antimicrobial lotion soap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer with nonantimicrobial lotion soap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial lotion soap alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonantimicrobial lotion soap alone
Number of subjects: 0
Study: 7726774

Group type: EXPERIMENTAL
Intervention: Integrated night vision goggle (NVG) helmets
Number of subjects: 10
Study: 2093235

Group type: EXPERIMENTAL
Intervention: Breastfeeding first child
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not breastfeeding first child
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education beyond high school
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short duration or unsuccessful breastfeeding experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not having education beyond high school or receiving anesthesia at later birth
Number of subjects: 0
Study: 215555

Group type: EXPERIMENTAL
Intervention: Erythromycin (40-50 mg/kg/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Amoxycillin (25-30 mg/kg/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Erythromycin (lower dosage)
Number of subjects: 3
Study: 31439593

Group type: EXPERIMENTAL
Intervention: Group A (2 mg naloxone, max 8 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group B (4 mg naloxone, max 16 mg/day)
Number of subjects: 20
Study: 27604303

Group type: EXPERIMENTAL
Intervention: Social and financial education training program (16 hours over 3 months)
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Control group (no program implemented)
Number of subjects: 1746
Study: 25074341

Group type: EXPERIMENTAL
Intervention: Family Intervention: Telephone Tracking ‐ Caregiver (FITT‐C)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Telephone Support (TS)
Number of subjects: 250
Study: 24428092

Group type: EXPERIMENTAL
Intervention: 10% onion extract in silicone derivative gel
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 22333169

Group type: EXPERIMENTAL
Intervention: Strengthening psychological and behavioral intervention combined with varenicline
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 111
Study: 19249412

Group type: EXPERIMENTAL
Intervention: CVAR implementation model training for GPs
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Usual care by GPs
Number of subjects: 1320
Study: 18038502

Group type: EXPERIMENTAL
Intervention: Vitaphenol Skin Cream (La Jolla Spa MD, La Jolla CA) applied to half of the face twice daily for 60 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream applied to half of the face twice daily for 60 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitaphenol Skin Cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 14742357

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight HES (HES 120; 20 mL/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-molecular-weight HES (HES 400; 20 mL/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4% human albumin (ALB)
Number of subjects: 45
Study: 17062502

Group type: EXPERIMENTAL
Intervention: Vibrant Med‐El Soundbridge (VSB) device implantation on the round window
Number of subjects: 7
Study: 10670263

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study: 8942302

Group type: EXPERIMENTAL
Intervention: Label group (child with ELD identified)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonlabel group (child with ELD not identified)
Number of subjects: 20
Study: 1821972

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of clomipramine at doses 75-300 mg daily for 7 to 16 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of maprotiline at doses 75-200 mg daily for 6 to 20 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both clomipramine and maprotiline
Number of subjects: 28
Study: 7032378

Group type: EXPERIMENTAL
Intervention: 32 mg/d methylprednisolone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inhaled beta agonists
Number of subjects: 46
Study: 31864822

Group type: EXPERIMENTAL
Intervention: Serial FGF‐23 measurements and FGF‐23 trajectory group membership
Number of subjects: 1597
Study: 31270970

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 30235727

Group type: EXPERIMENTAL
Intervention: Hanslim (high-dose)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Hanslim (low-dose)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 26685116

Group type: EXPERIMENTAL
Intervention: Advanced COPD
Number of subjects: 140

Group type: COMPARATOR
Intervention: Advanced cancer
Number of subjects: 140
Study: 24572581

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 22273590

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and cyclosporine A (CYA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anti-CCP positive RA patients (n=18)
Number of subjects: 40
Study: 20851055

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT), delivered via Internet or telephone, 8 sessions over 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 40
Study: 16884844

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16251607

Group type: EXPERIMENTAL
Intervention: SFA-rich diet (38% fat, 20% SFA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (38% fat, 22% MUFA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% fat, 55% CHO)
Number of subjects: 43
Study: 12408254

Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (carotid sinus massage)
Number of subjects: 175
Study: 10584723

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 150

Group type: COMPARATOR
Intervention: Incremental Sevoflurane
Number of subjects: 150

Group type: COMPARATOR
Intervention: 8% Sevoflurane
Number of subjects: 150
Study: 8664221

Group type: EXPERIMENTAL
Intervention: Oestradiol (5 mg/100 g)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 47
Study: 2190974

Group type: EXPERIMENTAL
Intervention: Aztreonam/metronidazole
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cefotaxime/metronidazole
Number of subjects: 154
Study: 30355509

Group type: EXPERIMENTAL
Intervention: Shortened Dental Arch (SDA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Partial Removable Dental Prostheses (PRDP)
Number of subjects: 150
Study: 30428039

Group type: EXPERIMENTAL
Intervention: Hydroxylated phosphatidylcholine (HPC) cluster
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Cluster including diglycerides and a monoglyceride with stearic acyl chain
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Cluster that included highly unsaturated phospholipids and cholesterol esters
Number of subjects: 787
Study: 26920606

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol therapy
Number of subjects: 514

Group type: COMPARATOR
Intervention: Aspirin therapy alone
Number of subjects: 514
Study: 24867575

Group type: COMPARATOR
Intervention: Dehydration-Placebo (DP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dehydration-Alcohol (DA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Partial Rehydration-Alcohol (PA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Full Rehydration-Alcohol (FA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alcohol (all trials)
Number of subjects: 14
Study: 22092541

Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined exercise training (A + R)
Number of subjects: 0
Study: 20171665

Group type: EXPERIMENTAL
Intervention: Acitretin (35 mg daily for 20 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16814823

Group type: EXPERIMENTAL
Intervention: Single-dose tafenoquine (400mg daily x 3 days)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Split-dose tafenoquine (200 mg twice daily x 3 days)
Number of subjects: 149
Study: 15823102

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Primary debulking surgery followed by platinum-based chemotherapy
Number of subjects: 60
Study: 12470183

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg per day
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg per day
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 9615912

Group type: EXPERIMENTAL
Intervention: Pravastatin (Pravachol), 20 mg twice daily for 12, 24, 48 and 72 hours preoperatively
Number of subjects: 36
Study: 7653451

Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 61

Group type: COMPARATOR
Intervention: quinidine
Number of subjects: 61
Study: 2712985

Group type: EXPERIMENTAL
Intervention: Out-patient physiotherapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Home mobilization advice by a physiotherapist
Number of subjects: 104

Group type: COMPARATOR
Intervention: Analgesia and cervical collar (Control)
Number of subjects: 104
Study: 728321

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 1000 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30259621

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) plus Pioglitazone (30 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dapagliflozin (10 mg) alone
Number of subjects: 28
Study: 28796547

Group type: EXPERIMENTAL
Intervention: Superior lamina approach
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Caudal bevel tip orientation
Number of subjects: 211

Group type: COMPARATOR
Intervention: Inferior lamina approach
Number of subjects: 211

Group type: COMPARATOR
Intervention: Cranial bevel tip orientation
Number of subjects: 211
Study: 25795524

Group type: EXPERIMENTAL
Intervention: Affect Labeling during exposure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (exposure without affect labeling)
Number of subjects: 0
Study: 23986524

Group type: EXPERIMENTAL
Intervention: Plyometric training group (PG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Machine-based resistance-training group (RG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 21121960

Group type: EXPERIMENTAL
Intervention: SLA implants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: modSLA implants
Number of subjects: 20
Study: 18786258

Group type: EXPERIMENTAL
Intervention: Belimumab (1.0, 4.0, 10, and 20 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Belimumab (two doses)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 16005853

Group type: EXPERIMENTAL
Intervention: Peripheral blood obtained from women after vaginal delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 0
Study: 11799651

Group type: EXPERIMENTAL
Intervention: Internet, therapist‐led (I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In‐person, therapist‐led (TL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 10369424

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg three times/day preprandially, adjusted to 1, 2 or 4 mg)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Glyburide (starting dose of 2.5 mg before breakfast, adjusted to 5 or 10 mg)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 576

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 576
Study: 7537355

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.25 U/kg/week)
Number of subjects: 20
Study: 1974664

Group type: EXPERIMENTAL
Intervention: Esmolol (n = 16)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 45
Study: 7386740

Group type: EXPERIMENTAL
Intervention: Insertion of a nasogastric tube
Number of subjects: 300

Group type: COMPARATOR
Intervention: No nasogastric tube
Number of subjects: 300
Study: 29333081

Group type: EXPERIMENTAL
Intervention: Innate immune cells
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acquired immune cells
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Peripheral blood T cells
Number of subjects: 10
Study: 27263034

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilostazol and/or Probucol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard statin therapy)
Number of subjects: 0
Study: 25661981

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring without alarms
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with alarms
Number of subjects: 160

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose
Number of subjects: 160
Study: 23816015

Group type: EXPERIMENTAL
Intervention: CHW-based intervention (1 household visit every 2 months for 12 months)
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Control group (no CHW visits)
Number of subjects: 2438

Group type: EXPERIMENTAL
Intervention: CHW-based intervention
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2438
Study: 20381657

Group type: EXPERIMENTAL
Intervention: Evidence-based antiplatelet and antithrombin therapies during the initial 24 hours of hospital admission
Number of subjects: 14070

Group type: EXPERIMENTAL
Intervention: In-hospital coronary angiography
Number of subjects: 14070

Group type: EXPERIMENTAL
Intervention: In-hospital outcomes
Number of subjects: 14070

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 14070

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 14070
Study: 18403080

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17187132

Group type: EXPERIMENTAL
Intervention: 360 degrees preequatorial retinal photocoagulation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prophylactic photocoagulation around predisposing lesions
Number of subjects: 35

Group type: COMPARATOR
Intervention: No preoperative retinal photocoagulation
Number of subjects: 35
Study: 15523399

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch 25 mg per day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 70
Study: 11122841

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy plus radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial chemotherapy followed by radiation therapy (combined modality therapy)
Number of subjects: 0
Study: 9065538

Group type: EXPERIMENTAL
Intervention: CSF levels of tau protein in patients with AD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal and neurologic controls
Number of subjects: 36
Study: 8320021

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 30
Study: 3525317

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg/day, 3 days/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 20
Study: 29789176

Group type: EXPERIMENTAL
Intervention: Telephonic counseling
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 305
Study: 27100726

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (1 gram in two divided doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Number of subjects: 43
Study: 24886440

Group type: EXPERIMENTAL
Intervention: Face-to-face guidance strategy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Direct mailing strategy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition (no guidance)
Number of subjects: 27
Study: 22392325

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-pharmacological methods
Number of subjects: 70
Study: 20347311

Group type: EXPERIMENTAL
Intervention: Follow-up clinic appointment two months after discharge
Number of subjects: 154

Group type: COMPARATOR
Intervention: No appointment (control)
Number of subjects: 154
Study: 18339258

Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (IMP) 50 mg daily
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal gel (VGP) 90 mg once daily
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal gel (VGP) 90 mg twice daily
Number of subjects: 412
Study: 15682477

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 79
Study: 12869088

Group type: COMPARATOR
Intervention: Quinine dihydrochloride (Qn) alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (Qn) with pentoxifylline (Px) (10 mg/kg/day for 3 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (Qn) with pentoxifylline (Px)
Number of subjects: 52
Study: 10941802

Group type: EXPERIMENTAL
Intervention: Aerobic endurance exercise (jogging, walking, cycling, swimming) for 12 weeks, average of 25 min two to three times a week at 50% of VO2max
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic endurance exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (sedentary FM patients)
Number of subjects: 27
Study: 8974891

Group type: EXPERIMENTAL
Intervention: Continuous electronic monitoring during labor
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intermittent auscultation of the fetal heart rate
Number of subjects: 8